GSEP
IMNM icon

Golden State Equity Partners’s Immunome IMNM Stock Holding History

Golden State Equity Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-950
Closed -$20.8K – 1001
2026
Q1 		$20.8K Buy
+950
New +$21.1K ﹤0.01% 1085

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Golden State Equity Partners's IMNM Position: Q2 2026 in Review

Golden State Equity Partners sold out of Immunome (IMNM) in Q2 2026, closing a stake of 950 shares — an estimated $20.8K sold.

Golden State Equity Partners first reported a position in IMNM in Q1 2026 and held it in 1 quarter. The position peaked at $20.8K in Q1 2026. 203 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • Golden State Equity Partners reported no remaining Immunome position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 950 Immunome shares in Q2 2026, an estimated $20.8K.
  • Golden State Equity Partners first reported a position in Immunome in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Immunome position peaked at $20.8K in Q1 2026.
  • 203 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.